VEGF gene polymorphisms and as a potential roles of bladder cancer recurrence factor
https://doi.org/10.17650/1726-9776-2024-20-4-120-126
Abstract
The study explores how certain variations in the VEGF (vascular endothelial growth factor) gene may influence the recurrence of bladder cancer, shedding light on its development and prognosis. Bladder cancer, mainly urothelial carcinoma, is complex and unpredictable, posing challenges for treatment. Understanding genetic factors, like VEGF gene variations, can help tailor treatment plans for better outcomes. The study highlights various pathways involved in bladder cancer progression, including the role of VEGF beyond just blood vessel growth. While some research suggests a connection between VEGF gene variations and bladder cancer risk, results vary. Identifying thesevariations could lead to personalized treatments and targeted therapies. However, more research is needed to understand how these genetic factors specifically affect cancer recurrence. Collaborative efforts and advanced studies are essential for improving bladder cancer management and patient outcomes.
About the Authors
G. P. Siregar
Doctoral Study Program, Faculty of Medicine, Universitas Padjadjaran; Division of Urology, Department of Surgery, Faculty of Medicine, Universitas Sumatera Utara
Indonesia
Competing Interests:
Indonesia
Ginanda Putra Siregar.
Bandung; Medan
Competing Interests:
None
I. Parwati
Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran
Indonesia
Competing Interests:
Indonesia
Ida Parwati.
Bandung
Competing Interests:
None
F. Safridai
Department of Urology, Faculty of Medicine, Universitas Padjadjaran
Indonesia
Competing Interests:
Indonesia
Ferry Safridai.
Bandung
Competing Interests:
None
T. Tjahjodjati
Department of Urology, Faculty of Medicine, Padjadjaran University, Hasan Sadikin Hospital
Indonesia
Competing Interests:
Indonesia
Tjahjodjati Tjahjodjati.
Bandung
Competing Interests:
None
References
1. Kaseb H., Aeddula N.R. Bladder Cancer. [Updated 2022 Oct 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK536923/
2. Humphrey P.A., Moch H., Cubilla A.L. et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and BladderTumours. Eur Urol 2016;70(1):106–19. DOI: 10.1016/j.eururo.2016.02.028
3. Fu D., Li P., Cheng W. et al. Impact of vascular endothelial growth factor gene-gene and gene-smoking interaction and haplotype combination on bladder cancer risk in Chinese population. Oncotarget 2017;8(14):22927–35. DOI: 10.18632/oncotarget.15287
4. Ferrara N. Vascular endothelial growth factors as a target for anticancer therapy. Oncologist 2004;9:2–10. DOI: 10.1634/theoncologist.9-suppl_1-2
5. Siregar G.P. Vascular endothelial growth factor polymorphism in bladder cancer: areview. Open Access Macedonian Journal of Medical Sciences (OAMJMS) 2020;8(F):31–6.
6. Van der Horst G., Bos L., van der Pluijm G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res 2012;10(8):995–1009. DOI: 10.1158/1541-7786.MCR-12-0274
7. Bakkar A.A., Wallerand H., Radvanyi F. et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63(23):8108–12.
8. Chan K.S., Espinosa I., Chao M. et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. PNAS 2009;106(33): 14016–21. DOI: 10.1073/pnas.0906549106
9. Thompson D.B., Siref L.E., Feloney M.P. et al. Immunological basis in the pathogenesis and treatment of bladder cancer. Expert Rev Clin Immunol 2015;11(2):265–79. DOI: 10.1586/1744666X.2015.983082
10. Marti H.H. Vascular Endothelial Growth Factor. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000–2013. Available at: https://www.ncbi.nlm.nih.gov/books/NBK6149/
11. Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost 2000;26(5):561–9. DOI: 10.1055/s-2000-13213
12. Robinson C.J., Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF)and their receptors. J Cell Sci 2001;114:853–65. DOI: 10.1242/jcs.114.5.853
13. Marti H.H., Risau W. Angiogenesis in ischemic disease. Thromb Haemost 1999;82 Suppl 1:44–52.
14. Wenger R.H. Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol 2000;203:1253–63.
15. Wafi S.B., Kallel A., Fradj M.K. et al. Haplotype-based association of vascular endothelial growth factor gene polymorphisms with urothelial bladder cancer risk in Tunisian population. J Clin Lab Anal 2018;32(9):e22610. DOI: 10.1002/jcla.22610
16. Cohen S.M., Shirai T., Steineck G. Epidemiology and etiology of premalignant and malignanturothelial changes. Scand J Urol Nephrol Suppl 2000;205:10515. DOI: 10.1080/00365590050509869
17. Garcia-Closas M., Malats N., Real F.X. et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms andbladder cancer risk. Plos Genetics 2007;3(2):287–93. DOI: 10.1371/journal.pgen.0030029
18. Fu D., Li P., Cheng W. et al. Impact of vascular endothelial growth factorgene-gene and gene-smoking interaction and haplotype combination on bladder cancer risk in Chinese population. Oncotarget 2017;8(14):22927–35. DOI: 10.18632/oncotarget.15287
19. Jaiswal P.K., Tripathi N., Shukla A., Mittal R.D. Association of single nucleotide polymorphismsin vascular endothelial growth factor gene with bladder cancer risk. Med Oncol 2013;30(2):509–16. DOI: 10.1007/s12032-013-0509-8
20. Yang Y., Zhang X., Song D., Wei J. Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk. Mol Clin Oncol 2014;2(4):501–5. DOI: 10.3892/mco.2014.296
21. Longo F., Biondi M.L., Inneo V. et al. Vascular endothelial growth factor (VEGF) genotypes, halotypes and risk of bladder cancer. Eur Urol Suppl 2009;8(4):227.
22. Henriquez-Hernandez L.A., Navarro P., Luzardo O.P. et al. Polymorphisms of glutathione S-transferase and, MDR1 and VEGF genes as riskfactors of bladder cancer: A case-control study. Urol Oncol 2012;30(5):660–5. DOI: 10.1016/j.urolonc.2010.08.02
Review
For citations:
Siregar G.P., Parwati I., Safridai F., Tjahjodjati T. VEGF gene polymorphisms and as a potential roles of bladder cancer recurrence factor. Cancer Urology. 2024;20(4):120-126. https://doi.org/10.17650/1726-9776-2024-20-4-120-126
Views:
97
Email this article 